Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e7813_ex99-1.htm EXIBIT 99.1 EXHIBIT 99.1 Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease New York, NY, July 3

Lockheed Martin will work with Australia’s Submarine Agency on sovereign combat systems integration for the Royal Australian Navy’s interim Virginia-class SSNs. The company secured a two-year A$26.5m contract to lead engineering and build a local supplier network, with about 20 CSI jobs in Western Australia. The AN/BYG-1 system will remain central.

Ondas (Nasdaq-listed) said it won an Israeli Defense Ministry tender to develop next-generation low-cost attack drones for the IDF, under the multimillion-dollar “Digital Bat” program. Ondas beat Elbit Systems and Rafael. The company valued at $5.3 billion reported shares up 10% after appointing David Barnea to lead its defense division.

Navitas Semiconductor filed a patent infringement lawsuit against Renesas Electronics in the US District Court for the Eastern District of Texas, alleging Renesas’ GaN product lines, including SuperGaN power semiconductors, infringe Navitas’ GaN patents (US Patent Nos. 9,929,079; 11,545,838; 11,770,010; 11,862,996). The dispute follows related litigation involving Wolfspeed and Navitas.

HII’s Mission Technologies division secured a $2.2 billion task order to support U.S. Southern Command under the STRINGRAI program, covering surveillance, tracking, intelligence, network services and global reconnaissance. HII said the work will expand SOUTHCOM intelligence and reconnaissance capabilities for operations against transnational criminal groups and drug cartels. The award runs a one-year base plus six options.

IMUNON (IMNN) reported Q2 2026 results and an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed advanced ovarian cancer. The company said enrollment is progressing faster than expected and expects completion in 1H 2029. It cited Phase 2 OVATION 2 median OS of 45.1 vs 30.4 months and MRD/ctDNA clearance improvements. Net loss was $2.8M.